



RESEARCH

Open Access

Methylation of the *SPARC* gene promoter and its clinical implication in pancreatic cancer

Jun Gao^{†1}, Jian Song^{†1}, Haojie Huang^{†1}, Zhaoshen Li^{*1}, Yiqi Du¹, Jia Cao¹, Minghui Li², Shunli Lv¹, Han Lin¹ and Yanfang Gong¹

Abstract

Background: The secreted protein acidic and rich in cysteine (*SPARC*) plays a pivotal role in regulating cell-matrix interactions and tumor angiogenesis, proliferation, and migration. Detection of *SPARC* gene methylation may be useful as a tumorigenesis marker for early detection of pancreatic cancer.

Methods: Methylation of the *SPARC* gene transcriptional regulation region (TRR) was detected using bisulfite-specific (BSP) PCR-based sequencing analysis in 40 cases of pancreatic cancer and the adjacent normal tissues, 6 chronic pancreatitis tissues, and 6 normal pancreatic tissues. BSP cloning-based sequencing analysis was also performed in selected cases. Clinicopathological data from the cancer patients were collected and analyzed.

Results: Analysis of *SPARC* gene TRR methylation showed two hypermethylation wave peak regions: CpG Region 1 (CpG site 1-7) and CpG Region 2 (CpG site 8-12). Pancreatic tissues have shown methylation in both regions with gradual increases from normal, chronic pancreatitis, and adjacent normal tissues to cancerous tissues. However, Methylation of CpG Region 2 was more sensitive than CpG Region 1 in pancreatic tumorigenesis. Furthermore, the methylation level of CpG Region 2 was associated with increased tumor size and exposure to the risk factors (tobacco smoke and alcohol consumption) for developing pancreatic cancer.

Conclusion: Methylation of the *SPARC* gene, specifically CpG Region 2, may be an early event during pancreatic tumorigenesis and should be further evaluated as a tumorigenesis marker for early detection of pancreatic cancer.

Background

Pancreatic cancer, one of the highly invasive and extremely lethal neoplasms, is the fifth leading cause of cancer death in the United States [1]. Pancreatic cancer mortality almost parallels its incidence, with a 5-year survival rate of less than 4%. Although surgical resection remains the only hope for long-term survival in patients with pancreatic cancer, the majority (~85%) of patients are found to be unresectable at diagnosis due to extensive local invasion and/or metastatic disease [2]. Therefore, early detection of pancreatic cancer is the key for improving survival of patients. Unfortunately, no early-detection markers currently are available for early diagnosis of pancreatic cancer, although many scientists are pursuing pancreatic cancer research and believe that early detec-

tion of pancreatic cancer using molecular gene markers may be possible in the future [3,4].

To date, it is clear that many genetic and epigenetic alterations occur during pancreatic tumorigenesis [5]. Among these alterations, methylation of the tumor suppressor gene promoter results in gene silencing [6], which may take place during the very early stages of pancreatic cancer development. Detection of such aberrant DNA methylation of tumor suppressor genes could be used as a diagnostic marker for pancreatic cancer [7]. Thus, defining altered gene expression and understanding the underlying molecular mechanism in pancreatic cancer are urgently needed.

Secreted protein acidic and rich in cysteine (*SPARC*)/osteonectin/BM 40 is a matricellular glycoprotein that is involved in diverse biological processes, including tissue remodeling, wound repair, morphogenesis, cell differentiation, proliferation, migration, and angiogenesis [8-11]. A previous study showed that the *SPARC* gene promoter is

* Correspondence: lizhaoshen111@yahoo.com.cn

¹ Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

[†] Contributed equally

Full list of author information is available at the end of the article

aberrantly methylated in primary pancreatic cancer tissue [12]. Gene expression profiling using oligonucleotide microarray and reverse transcription-PCR analyses demonstrated that *SPARC* mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells but not in the majority of pancreatic cancer cell lines [12]. The conditioned medium containing secreted *SPARC* protein suppressed the growth of pancreatic cancer cells, indicating that silencing of the *SPARC* gene may result in pancreatic cancer development and progression [12].

In the current study, we detected the methylation levels and methylation pattern of the *SPARC* gene transcriptional regulation region (TRR) in normal, adjacent normal, chronic pancreatitis, and pancreatic cancer tissues to assess the altered methylation levels of the *SPARC* gene to determine if *SPARC* methylation can be used as a tumorigenesis marker for the early detection of pancreatic cancer.

Methods

Cell line and culture

Pancreatic cancer cell line PANC1 was purchased from the American Type Culture Collection (Manassas, VA, USA) and PaTu8988 was a kind gift from Dr. H.P. Elsassner (Phillips University, Marburg, Germany). These cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (both were from Life Technologies Inc., Rockville, MD, USA) and incubated at 37°C in a humidified chamber with 95% air and 5% CO₂.

Patient tissue specimens

A tissue and patient's data usage protocol was approved by the Ethics Committee of our institution. Informed written consent was obtained from each patient. Tissue samples from 52 patients were obtained from the Second Military Medical University affiliated Changhai Hospital from August 2006 to December 2007; these samples were from 6 pathologically proven cases of chronic pancreatitis, 6 cases of normal pancreatic tissues, 40 cases of pancreatic cancer (ductal adenocarcinoma type), and corresponding normal tissue from those same 40 patients. The tissue samples were obtained and stored in liquid nitrogen immediately after being resected in the operating room. For pancreatic cancer cases, tumor tissues that contained more than 70% tumor cells and the corresponding adjacent normal tissues without any tumor cell infiltration were selected. In addition, samples of white blood cells (WBCs) were obtained from two healthy volunteers. Clinicopathological data, including gender, age, status of tobacco smoking and alcohol consumption, tumor size, differentiation, lymph node metastasis, and TNM stages, were collected from the electronic medical records of the patients. Tobacco smoking was

defined as at least one cigarette per day for no less than 1 year. Alcohol consumption was defined as intake of at least 50 ml of Chinese liquor, 250 ml of wine, or 500 ml of beer at least once a week for a minimum of 1 year. The 6th American Joint Committee on Cancer (AJCC) staging system was used to classify the clinical stage of pancreatic cancer.

DNA extraction and bisulfite modification of DNA

Genomic DNA from the tissues and cell lines was extracted using the phenol/chloroform method and precipitated with ethanol. One microgram of genomic DNA was subjected to treatment with the EZ DNA Methylation Kit™ (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions. The bisulfite modified DNA was then suspended in 20 µl of deionized water and used immediately or stored at -80°C until use.

Bisulfite-specific (BSP) PCR and DNA sequencing

The primers used to detect methylation of the *SPARC* gene promoter TRR were designed to specifically amplify bisulfite-converted DNA of *SPARC* TRR. The primers were 5'-ATTTAGTTTAGAGTTTTG-3' (forward) and 5'-ACAAACTTCCCTCCCTTAC-3' (reverse) and were custom synthesized by Shanghai Sangon (Shanghai, China). Two microliters of the bisulfite modified DNA from each sample were subjected to PCR analysis in a 25 µL volume containing 1 × PCR buffer, 2.0 mmol/L MgCl₂, 2.5 mmol/L dNTP, 1 mmol/L primer, and EX Taq DNA HS 800 U/L. The reaction mixture was preheated at 95°C for 5 min and amplified using a touch-down PCR program (i.e., 9 cycles of 95°C for 30 s, 59°C for 30 s (next cycle touch-down 0.5°C) and 72°C for 30 s; 42 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and a final extension of 4 min at 72°C. The PCR products were then subjected to either direct sequencing analysis or cloning into the pMD-18-T vector (TaKaRa, Dalian, China) followed by sequencing analysis (after the cloning, 10-25 clones from each sample were randomly selected for DNA sequencing).

Sequencing data analysis

Sequencing analysis was performed by Shanghai Invitrogen Biotech Co. Ltd (Shanghai, China). For the data obtained from BSP PCR-based sequencing analysis, the percentage of methylation of each CpG site in a given sample was calculated as the height of the "C" peak divided by the sum of the height of "C" + "T". For the data obtained from BSP cloning-based sequencing analysis, the percentage of methylation of each CpG site in a given sample was calculated as the number of the methylated CpG sites divided by the total observed sequenced clone numbers. The percentage of the region methylation in a

given sample was the average of each CpG site in the DNA region.

Statistical analysis

Statistical analyses were conducted using SPSS version 15.0 (SPSS, Chicago, IL, USA). A one-way ANOVA test was performed to analyze differences in the percentage of the region methylation among pancreatic cancer tissues, adjacent normal pancreatic tissues, chronic pancreatitis tissues, and normal pancreatic tissues. General linear model univariate analysis was performed to determine the correlations of *SPARC* methylation with clinical characteristics of pancreatic cancer. All variables were subsequently analyzed using a stepwise multiple regression to assess their independent contribution to the methylation level, with entry and removal at the 0.05 and 0.1 significance levels, respectively.

Results

Methylation of the *SPARC* gene TRR in pancreatic tissues and pancreatic cancer cells

According to the NCBI genome database, we analyzed the *SPARC* gene TRR and found a CpG island around the transcriptional start site (designated as '0') between the upstream -29 bp and downstream +191 bp using the methylation analysis software of Methyl Primer Express v1.0 (ABI). Figure 1A illustrates the structure of the *SPARC* gene and the topology of the BSP primer, indicating the position of the CpG island containing 12 CpG sites and the BSP primers.

We next performed BSP PCR-based sequencing analysis to assess the methylation status of the *SPARC* gene TRR in four tissue groups: 40 pancreatic cancer samples and their corresponding adjacent normal pancreatic tissues, 6 chronic pancreatitis samples, and 6 real normal pancreatic tissue samples. Figure 1B shows representative BSP PCR-based sequencing analysis results for these four different groups of pancreatic tissues. The methylation pattern of the *SPARC* gene TRR in these four types of pancreatic tissues is shown in Figure 2. According to the curve fitted to the mean percent methylation of pancreatic cancer tissue data by the MACD (moving average convergence/divergence) method, we found two hypermethylation wave peak regions in these CpG islands. The first contained CpG site 1-7 (CpG Region 1) and the second contained CpG sites 8-12 (CpG Region 2). We searched the web site <http://www.cbrc.jp/research/db/TFSEARCH.html> and found that CpG Region 1 contained two Sp1 sites while CpG Region 2 contained one Ap1 site (Figure 1A). Figure 3 shows the mean percentage of gene methylation and the 95% CI of these two hypermethylation wave peak regions in the four types of pancreatic tissues. Methylation of these two regions appeared to gradually increase from normal, chronic pancreatitis, and




Figure 1 Detection of *SPARC* gene TRR methylation. (A) Illustration of the *SPARC* gene TRR and topology of the BSP primer. The black bar indicates the analyzed region. The bold "G" indicates the transcriptional start site. The bold italic "CG" indicates the location of 12 CpG island sites. The underlined sequence indicates the primers for BSP. Blue and red rectangles indicate the Sp1 and AP1 binding consensus sequences, respectively. The red triangles indicate the region whose representative sequence analyses were showed in Figure 1B. (B) Representative sequencing data of the *SPARC* gene TRR in four different groups of pancreatic tissues obtained using BSP PCR-based sequencing analysis. CpG dinucleotides "C" in the objective sequence are shown in red. The red, yellow, green, light blue, and deep blue dots under the analyzed sequence represent different methylation ratios, respectively.

adjacent normal to pancreatic cancer tissues. Furthermore, CpG Region 2 was rarely methylated in real normal




Figure 2 Methylation pattern of the *SPARC* gene TRR in pancreatic tissue samples. The pattern consists of two hypermethylation wave peak regions including CpG region 1 (CpG site 1--7) and CpG region 2 (CpG site 8--12). The curve was fitted to the mean methylation ratios of pancreatic cancer tissues using the MACD (moving average convergence/divergence) method.




Figure 3 Methylation level of CpG region 1 (A) and CpG region 2 (B) in the SPARC gene TRR in pancreatic tissues. All data are reported as means \pm 95% CI. #, the pancreatic cancer tissues are compared to the corresponding tumor adjacent normal tissues, chronic pancreatitis tissues, or normal pancreatic tissues, $p < 0.05$. &, the corresponding tumor adjacent normal tissues are compared to the real normal pancreatic tissues, $p < 0.05$.

pancreatic tissues but CpG Region 1 was more frequently methylated in some of normal tissues. In addition, the methylation level of CpG Region 2 in the adjacent normal tissues was significantly increased compared with the normal tissues. These results indicate that methylation of CpG Region 2 may be a more sensitive marker and an early event during pancreatic tumorigenesis.

To further confirm that hypermethylation of the SPARC gene TRR occurs in pancreatic cancer, we also performed BSP cloning-based sequencing analysis in two pancreatic cancer cell lines (PANC1 and Patu8988), three cases of pancreatic cancer and adjacent normal tissues, two cases of normal pancreatic tissues, and two cases of WBCs from healthy volunteers. Figure 4 shows the methylation pattern of the SPARC gene TRR in these samples. The two pancreatic cancer cell lines and two-thirds of the pancreatic cancer tissues (PC09 and PC179, but not PC186) obviously presented two hypermethylation wave peak regions (CpG Region 1 and CpG Region 2) in the CpG islands compared to the adjacent normal and normal tissues and the WBCs from the healthy volunteers. These data confirmed the results of the BSP PCR-based sequencing analysis.

Association of SPARC gene TRR methylation with clinicopathological parameters in patients with pancreatic cancer

We collected clinicopathological data from the patients and then analyzed the association of SPARC gene TRR methylation with clinicopathological parameters in patients with pancreatic cancer. General linear model univariate analysis showed that the percentage of CpG Region 2 methylation was associated with larger tumor size, tobacco smoking, and alcohol consumption (Table 1). Multiple regression analysis also showed that the factors of larger tumor size, tobacco smoking, and alcohol consumption were independent contributors to the percentage of CpG Region 2 methylation (Table 2).

Discussion

In the current study, we determined the methylation status of the SPARC gene promoter in pancreatic cancer cell lines, pancreatic cancer and corresponding adjacent normal pancreatic tissues, chronic pancreatitis tissues, and real normal pancreatic tissues. Methylation of the SPARC gene TRR gradually increased from normal, chronic pancreatitis, and the adjacent normal tissues to pancreatic cancer tissues. The methylation pattern of the SPARC gene TRR exhibited two hypermethylation wave peak regions: CpG Region 1 (CpG site 1-7) and CpG Region 2 (CpG site 8-12). CpG Region 2 was rarely methylated in real normal pancreatic tissues but CpG Region 1 was more frequently methylated. In addition, the methylation level of CpG Region 2 in the adjacent normal tissues was

significantly increased compared with the real normal tissues. Furthermore, the aberrant hypermethylation of CpG Region 2 was associated with larger tumor size, tobacco smoking, and alcohol consumption. Our results indicated that methylation of CpG Region 2 could be further evaluated as a tumorigenesis marker for the early diagnosis of pancreatic cancer.

It is known that chronic pancreatitis is considered to be a precancerous lesion [13] and that cancer-adjacent tissues experience "the field effect of carcinogenesis," which is evident because they show the same genetic changes as the tumor [14,15]. In this study, we found that CpG Region 2 was hypermethylation in corresponding tumor adjacent normal pancreatic tissues and chronic pancreatitis tissues, and additionally that its hypermethylation correlated with pancreatic cancer risk factors (tobacco smoking and alcohol consumption) [13,16]. These data showed that hypermethylation of CpG Region 2 is an early event in pancreatic cancer tumorigenesis.

Brune et al. demonstrated that aberrant methylation of the SPARC gene promoter as a marker of sporadic pancreatic adenocarcinoma can also be used to detect familial pancreatic adenocarcinoma [7]. Sato et al. showed that the SPARC gene promoter was methylated in pancreatic cancer juice with sensitivity of 90.9% and specificity of 70.4% for pancreatic cancer diagnosis [17]. These studies utilized a conventional MSP method to detect SPARC gene methylation. In the current study, we not only confirmed the published data about methylation of the SPARC gene promoter in pancreatic cancer, but we also further revealed the methylation level of the different sites of the CpG island. In particular, our data showed that the methylation pattern of the SPARC gene TRR exhibited two hypermethylation wave peak regions. The methylation level of CpG Region 1 was higher in pancreatic cancer tissue than in normal, chronic pancreatitis, and the adjacent normal tissues, but CpG Region 1 of the SPARC gene also was methylated in normal pancreatic tissues. In contrast, CpG Region 2 was only methylated in pancreatic cancer, adjacent normal, and chronic pancreatitis tissues. These data suggest that methylation of CpG Region 2 is a more sensitive marker to detect early alteration in pancreatic cancer.

Aberrant methylation of the SPARC gene has been reported in various kinds of tumors, including lung and colorectal cancer, acute myeloid leukemia, multiple myeloma, endometrial cancer, ovarian cancer, cervical cancer, pancreatic cancer, and prostate cancer [18-25]. Infante et al. reported that there were four expression patterns of the SPARC gene in pancreatic cancer tissues: tumor-/stroma- (16%); tumor+/stroma- (17%); tumor-/stroma+ (52%); and tumor+/stroma+ (15%) [26]. Sato et al. reported that SPARC mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells (79%) but not




Figure 4 Methylation status of 12 CpG island sites and the methylation level of CpG Region 1 and CpG Region 2 in the samples determined using BSP cloning-based sequencing analysis. BSP cloning-based sequencing analysis was performed on real normal pancreatic tissues (N4 and N7), white blood cells (W6 and W8) of two healthy volunteers, pancreatic cancer cell lines (PANC1 and Patu8988), pancreatic cancer tissues (PC09, PC179, and PC186), and the corresponding adjacent normal tissues (PN09, PN179, and PN186). Black dot, methylated; white dot, unmethylated.

in pancreatic cancer cell lines (0/17) or the majority of primary pancreatic cancer tissues (68%) and that methylation of the *SPARC* gene promoter was responsible for gene silencing [12].

The molecular mechanism responsible for methylation of the *SPARC* gene promoter is unknown. Recent studies demonstrated that some environmental factors (such as tobacco smoke) can cause methylation of certain tumor suppressor genes [14,27]. In pancreatic cancer, tobacco smoke can induced k-ras gene mutation and p16 and ppENK gene methylation [28,29]. Our data showed that exposure to risk factors such as tobacco smoke and alco-

hol use was associated with methylation of CpG Region 2 in the *SPARC* gene promoter in pancreatic cancer tissues. Our data may indicate that these risk factors cause pancreatic cancer development and progression through induction of *SPARC* gene methylation.

The *SPARC* gene may play a role in suppression of tumorigenesis, including pancreatic cancer. Molecularly, the *SPARC* protein binds to a number of different extracellular matrix components, such as thrombospondin 1, vitronectin, entactin/nidogen, fibrillar collagens (types I, II, III, and V), and collagen type IV. *SPARC* has the potential to contribute to the organization of the matrix in connec-

Table 1: Correlations of SPARC methylation with clinical characteristics of pancreatic cancer

Clinical characteristics	Cases (n = 40)	Methylation ratio (%)					
		Region 1	p	Region 2	p	Total	p
Gender							
Male	25	58.6 ± 11.8	0.709	53.6 ± 18.7	0.265	56.5 ± 11.9	0.337
Female	15	59.8 ± 12.1		55.5 ± 22.6		58.0 ± 13.2	
Age (yrs)							
≤ 55	19	58.0 ± 12.0	0.386	52.6 ± 19.1	0.156	55.7 ± 12.1	0.142
> 55	21	60.0 ± 11.7		56.0 ± 21.0		58.3 ± 12.6	
Alcohol							
--	20	58.7 ± 12.9	0.794	46.6 ± 18.2	0.016	53.7 ± 11.2	0.154
+	20	60.0 ± 11.7		62.1 ± 19.1		60.5 ± 12.6	
Smoking							
--	22	58.1 ± 13.7	0.671	47.5 ± 17.5	0.017	53.7 ± 11.9	0.067
+	18	60.2 ± 9.1		62.8 ± 19.1		61.3 ± 11.7	
Tumor size (cm)							
≤ 2	21	55.4 ± 10.5	0.087	46.1 ± 18.8	0.029	51.5 ± 10.1	0.013
> 2	19	63.1 ± 12.0		63.5 ± 17.4		63.3 ± 11.7	
Differentiation							
Moderate	19	59.6 ± 12.2	0.625	53.6 ± 20.4	0.799	57.1 ± 12.4	0.877
Poor	21	58.6 ± 11.6		55.0 ± 20.1		57.1 ± 12.5	
Lymph node metastasis							
--	23	60.4 ± 12.4	0.307	53.7 ± 20.0	0.832	57.6 ± 12.5	0.421
+	17	57.2 ± 10.9		55.2 ± 20.7		56.4 ± 12.3	
pTNM stage							
I+II	21	58.2 ± 12.4	0.444	51.9 ± 20.1	0.867	55.5 ± 12.6	0.543
III+IV	19	60.0 ± 11.2		57.1 ± 20.0		58.8 ± 12.0	

Correlations of SPARC methylation with clinical characteristics of pancreatic cancer were determined by general linear model univariate analysis.

tive tissue as well as basement membranes to regulate cell-cell interaction and differentiation to modulate cell growth. However, to date, it remains to be determined whether SPARC is a tumor suppressor gene or an oncogene. It is because both kinds of data were published and available in Pubmed. Particularly, two papers showed that SPARC wasn't expressed in the majority of primary pancreatic cancer tissues (68%~69%)[12,26], whereas another study found high expression of SPARC in almost all tumor tissues [30]. Furthermore, all these three papers reported strong staining of SPARC in fibroblasts and the extracellular matrix. Moreover, Podhajcer et al. [31] reported that SPARC gene expression was associated with good prognosis. In addition, the in vitro experiment showed that the expression of SPARC inhibited growth of

cancer cells [12,30], but promoted invasion of pancreatic tumor cells [30]. Another study, however, showed that inhibition of endogenous SPARC enhanced pancreatic cancer cell growth [32]. In our current study, we found that methylation of the SPARC gene is an early event during pancreatic carcinogenesis, which supports the premise that this gene is a tumor suppressor gene. Although we didn't show expression data of SPARC, it is obvious that methylation of gene promoter surely silences the gene expression. Taken altogether, this discrepancy warrants further investigation.

Regulation of gene expression by the de novo methylation is involved in tumorigenesis [33]. De novo methylation is a progressive process rather than a single event and is neither site specific nor completely random but

Table 2: The standardized coefficient beta value of multiple regression analysis

Clinical characteristics	Region 1	Region 2	Whole region
Gender	--	--	--
Age	--	--	--
Alcohol	--	0.341 ($p = 0.012$)	--
Smoking	--	0.336 ($p = 0.013$)	--
Tumor size	0.332 ($p = 0.036$)	0.342 ($p = 0.013$)	0.485 ($p = 0.002$)
Differentiation	--	--	--
Lymph node metastasis	--	--	--
pTNM stage	--	--	--
Adjusted R^2	0.087	0.367	0.215

Clinical characteristics of pancreatic cancer were analyzed using a stepwise multiple regression to assess their independent contribution to the methylation level, with entry and removal at the 0.05 and 0.1 significance levels, respectively.

instead is region specific. Recognition and methylation of differentially methylated regions by DNA methyltransferase involves the detection of both nucleosome modification and CpG spacing, giving rise to methylation in a periodic pattern on the DNA [34]. On the other hand, many researchers have found that transcription factors (e.g., c-Myb, c-Myc/Myn, E2F, CREB, Ap1, Ap2, Sp1, and NF- κ B) are incapable of binding to methylated DNA of their recognition sequences and that gene transcription therefore is blocked [35,36]. The identification of region-specific methylation patterns in genes may be essential for an accurate assessment of methylation-mediated transcriptional silencing [37]. In this study, two Sp1 and one AP1 sites were identified in the *SPARC* gene TRR and the AP1 site is localized at CpG Region 2 (covering CpG site 10 and CpG site11). However, the biological significance of these SP1 and AP1 sites in the *SPARC* gene will require further study.

In summary, our current data demonstrated different methylation levels of the *SPARC* gene TRR CpG sites. Methylation of CpG Region 2 was more sensitive than CpG Region 1 in pancreatic tumorigenesis, suggesting that aberrant hypermethylation of CpG Region 2 may be useful as a tumorigenesis marker for early detection of pancreatic cancer. However, this finding needs to be verified in a study with a larger sample size of patients with pancreatic cancer.

List of abbreviations

SPARC: secreted protein acidic and rich in cysteine; TTR: transcriptional regulation region; BSP: Bisulfite-specific; PANC1: a pancreatic cancer cell line; PaTu8988: a pancreatic cancer cell line; DMEM: Dulbecco's modified Eagle's medium; WBC: white blood cell.

Authors' information

Jun Gao, PH.D and MD, Director of the Pancreatic Disease Research Center affiliated to Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Manager for the National Scientific Technologic Supporting Project [2006BAI02A12] of "Methods for early pancreatic cancer diagnosis".

Zhaoshen Li, MD, Professor, Maste of Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. The Chairman of Chinese Society of Digestive Endoscopy. Leader of the National Scientific Technologic Supporting Project [2006BAI02A12] of "Methods for early pancreatic cancer diagnosis".

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JG and JS designed the study, wrote the manuscript and performed the statistical analysis. HH participated in its design and participated in the sequence alignment. ZL conceived of the study, and participated in its design. YD and YG collected all the human material and participated DNA extraction and bisulfite modification of DNA. JC, ML, SL and HL performed the methylation detection. JG, JS and HH contributed equally to this work. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the National Scientific Technologic Supporting Project Fund [2006BAI02A12]. We thank Shanghai Biochip Co. Ltd (China) for providing the technologic platform, Juan Song and Beibei Zhou of Shanghai Biochip Co. Ltd. (China) for technical support, and Professor Xiangui Hu of Changhai Hospital at The Second Military Medical University, Shanghai, China, for providing the tissue samples. We declare that we have no conflict of interest.

Author Details

¹Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China and ²Shanghai Biochip Co. Ltd, Shanghai 200433, China

Received: 30 December 2009 Accepted: 26 March 2010
Published: 26 March 2010

References

- Jemal A, Tiwari RC, Murray T, Samuels A, Ward E, Feuer EJ, Thun MJ: **Cancer statistics, 2004.** *CA Cancer J Clin* 2004, **54**(1):8-29.
- Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ: **Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis.** *Cancer* 2009, **115**(11):2420-2429.
- Gao J, Li Z, Chen Z, Shao J, Zhang L, Xu G, Tu Z, Gong Y: **Antisense Smo under the control of the PTCH1 promoter delivered by an adenoviral vector inhibits the growth of human pancreatic cancer.** *Gene Ther* 2006, **13**(22):1587-1594.
- Wang W, Gao J, Man XH, Li ZS, Gong YF: **Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.** *Oncol Rep* 2009, **21**(6):1439-1447.
- Feinberg AP, Tycko B: **The history of cancer epigenetics.** *Nat Rev Cancer* 2004, **4**(2):143-153.
- Ushijima T: **Detection and interpretation of altered methylation patterns in cancer cells.** *Nat Rev Cancer* 2005, **5**(3):223-231.
- Brune K, Hong SM, Li A, Yachida S, Abe T, Griffith M, Yang D, Omura N, Eshleman J, Canto M, Schulick R, Klein AP, Hruban RH, Iacobuzio-Donahue C, Goggins M: **Genetic and epigenetic alterations of familial pancreatic cancers.** *Cancer Epidemiol Biomarkers Prev* 2008, **17**(12):3536-3542.
- Bradshaw AD, Sage EH: **SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury.** *J Clin Invest* 2001, **107**(9):1049-1054.
- Brekken RA, Sage EH: **SPARC, a matricellular protein: at the crossroads of cell-matrix communication.** *Matrix Biol* 2001, **19**(8):816-827.
- Jendraschak E, Sage EH: **Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology.** *Semin Cancer Biol* 1996, **7**(3):139-146.
- Yan Q, Sage EH: **SPARC, a matricellular glycoprotein with important biological functions.** *J Histochem Cytochem* 1999, **47**(12):1495-1506.
- Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, Goggins M: **SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.** *Oncogene* 2003, **22**(32):5021-5030.
- Lowenfels AB, Maisonneuve P: **Risk factors for pancreatic cancer.** *J Cell Biochem* 2005, **95**(4):649-656.
- Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, Ushijima T: **The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers.** *Cancer* 2009, **115**(15):3412-3426.
- Chai H, Brown RE: **Field effect in cancer-an update.** *Ann Clin Lab Sci* 2009, **39**(4):331-337.
- Raimondi S, Maisonneuve P, Lowenfels AB: **Epidemiology of pancreatic cancer: an overview.** *Nat Rev Gastroenterol Hepatol* 2009, **6**(12):699-708.
- Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, Yeo CJ, Kalloo A, Hruban R, Goggins M: **DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.** *Cancer Res* 2006, **66**(2):1208-1217.
- Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N: **Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis.** *Cancer Epidemiol Biomarkers Prev* 2006, **15**(1):114-123.
- Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, Gazdar AF: **Aberrant methylation of SPARC in human lung cancers.** *Br J Cancer* 2005, **92**(5):942-948.
- Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT: **SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'-deoxycytidine to increase SPARC expression and improve therapy response.** *Br J Cancer* 2008, **98**(11):1810-1819.
- DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV: **Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein.** *Leukemia* 2006, **20**(3):426-432.
- Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J, Zochbauer-Muller S: **Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.** *Cancer Res* 2008, **68**(1):44-54.
- Rodriguez-Jimenez FJ, Caldes T, Iniesta P, Vidart JA, Garcia-Asenjo JL, Benito M: **Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma.** *Oncol Rep* 2007, **17**(6):1301-1307.
- Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K: **Aberrant promoter methylation of SPARC in ovarian cancer.** *Neoplasia* 2009, **11**(2):126-135.
- Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M: **Survey of differentially methylated promoters in prostate cancer cell lines.** *Neoplasia* 2005, **7**(8):748-760.
- Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M: **Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.** *J Clin Oncol* 2007, **25**(3):319-325.
- Chang HW, Ling GS, Wei WJ, Yuen AP: **Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma.** *Cancer* 2004, **101**(1):125-132.
- Duell EJ, Bracci PM, Moore JH, Burk RD, Kelsey KT, Holly EA: **Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer.** *Cancer Epidemiol Biomarkers Prev* 2008, **17**(6):1470-1479.
- Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D: **K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.** *Pancreas* 2007, **34**(1):55-62.
- Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Buchler MW, Berger MR, Friess H: **Osteonectin influences growth and invasion of pancreatic cancer cells.** *Ann Surg* 2005, **242**(2):224-234.
- Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: **The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.** *Cancer Metastasis Rev* 2008, **27**(4):691-705.
- Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M, Kornmann M: **Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.** *Br J Cancer* 2010, **102**(1):188-195.
- Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrlich M, He T, Meissner A, Jaenisch R: **Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing.** *Genes Dev* 2007, **21**(23):3110-3122.
- Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X: **Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation.** *Nature* 2007, **449**(7159):248-251.
- Li D, Da L, Tang H, Li T, Zhao M: **CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding.** *Nucleic Acids Res* 2008, **36**(1):330-341.
- Zhang H, Darwanto A, Linkhart TA, Sowers LC, Zhang L: **Maternal cocaine administration causes an epigenetic modification of protein kinase Cepsilon gene expression in fetal rat heart.** *Mol Pharmacol* 2007, **71**(5):1319-1328.
- Wong DJ, Foster SA, Galloway DA, Reid BJ: **Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest.** *Mol Cell Biol* 1999, **19**(8):5642-5651.

doi: 10.1186/1756-9966-29-28

Cite this article as: Gao et al., Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer *Journal of Experimental & Clinical Cancer Research* 2010, **29**:28